Our science

Target Discovery & Validation

iTeos establishes innovative platforms that reproduce immunosuppression induced by different components of the tumor microenvironment.

Cutting edge in vitro and ex-vivo assays deployed on iTeos human-based phenotypic platforms are used for the identification of rational combinations of molecules identified in our current programs, as well as the discovery of novel targets for immuno-oncology. This effort is complemented by collaborations with top tier universities throughout the world to profile cancer samples of patients treated with immunotherapies. Those studies have as objectives to investigate the heterogeneity of tumors and Tumor microenvironment, as well as to identify genomic determinants associated with immune responsiveness.